

# S Intidhar Labidi-Galy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2789488/publications.pdf>

Version: 2024-02-01

41  
papers

3,033  
citations

331670

21  
h-index

233421

45  
g-index

47  
all docs

47  
docs citations

47  
times ranked

5924  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.. Journal of Clinical Oncology, 2022, 40, 5571-5571.	1.6	2
2	Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Seminars in Cancer Biology, 2021, 77, 127-143.	9.6	59
3	Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?. Cancer Treatment Reviews, 2021, 97, 102204.	7.7	24
4	Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. European Journal of Cancer, 2021, 152, 68-77.	2.8	18
5	Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell, 2021, 39, 1091-1098.e2.	16.8	199
6	PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. Cancer Treatment Reviews, 2021, 99, 102255.	7.7	25
7	Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. Gynecologic Oncology, 2020, 156, 377-386.	1.4	14
8	Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation. Gynecologic Oncology Reports, 2020, 33, 100600.	0.6	8
9	Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Scientific Reports, 2020, 10, 7073.	3.3	57
10	Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis.. Journal of Clinical Oncology, 2020, 38, 1087-1087.	1.6	2
11	Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targetsâ€”a narrative review. Annals of Translational Medicine, 2020, 8, 1712-1712.	1.7	36
12	Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. Gynecologic Oncology, 2019, 155, 262-269.	1.4	19
13	BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients. Breast Cancer Research and Treatment, 2019, 174, 775-783.	2.5	15
14	Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian Cancer. Clinical Cancer Research, 2018, 24, 326-333.	7.0	40
15	Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. Journal of Pathology, 2018, 246, 459-469.	4.5	23
16	Clinical Development of Anti-mitotic Drugs in Cancer. Advances in Experimental Medicine and Biology, 2017, 1002, 125-152.	1.6	22
17	High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications, 2017, 8, 1093.	12.8	515
18	Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response. Critical Reviews in Oncology/Hematology, 2016, 101, 50-59.	4.4	40

#	ARTICLE	IF	CITATIONS
19	Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. <i>Oncogene</i> , 2015, 34, 373-383.	5.9	42
20	Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 542-550.	1.4	128
21	Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. <i>Gynecologic Oncology</i> , 2014, 132, 328-333.	1.4	17
22	Breast cancer-derived transforming growth factor- $\beta^2$ and tumor necrosis factor- $\alpha$ compromise interferon- $\gamma$ production by tumor-associated plasmacytoid dendritic cells. <i>International Journal of Cancer</i> , 2013, 133, 771-778.	5.1	80
23	CD4 lymphopenia to identify end-of-life metastatic cancer patients. <i>European Journal of Cancer</i> , 2013, 49, 1080-1089.	2.8	31
24	Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. <i>Oncoimmunology</i> , 2012, 1, 380-382.	4.6	114
25	Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. <i>Oncoimmunology</i> , 2012, 1, 432-440.	4.6	102
26	Impaired IFN- $\gamma$ Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression. <i>Cancer Research</i> , 2012, 72, 5188-5197.	0.9	285
27	First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer. <i>Bulletin Du Cancer</i> , 2012, 99, E18-E25.	1.6	3
28	Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer. <i>Cancer Research</i> , 2011, 71, 5423-5434.	0.9	200
29	Therapeutic pipeline for soft-tissue sarcoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2479-2491.	1.8	9
30	Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study. <i>Bulletin Du Cancer</i> , 2011, 98, E80-E89.	1.6	6
31	Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 187-195. <sup>2,5</sup>		10
32	Serum cytokines in follicular lymphoma. Correlation of TGF- $\beta^2$ and VEGF with survival. <i>Annals of Hematology</i> , 2010, 89, 25-33.	1.8	34
33	Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. <i>Bulletin Du Cancer</i> , 2010, 97, E23-E32.	1.6	21
34	Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas. <i>Cancer Research</i> , 2009, 69, 5383-5391.	0.9	610
35	Bevacizumab and Paclitaxel for Breast Cancer Patients with Central Nervous System Metastases: A Case Series. <i>Clinical Breast Cancer</i> , 2009, 9, 118-121.	2.4	58
36	Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan. <i>International Journal of Hematology</i> , 2008, 88, 291-293.	1.6	8

#	ARTICLE	IF	CITATIONS
37	Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin. <i>BMC Cancer</i> , 2008, 8, 28.	2.6	32
38	Inflammatory breast cancer in Tunisia in the era of multimodality therapy. <i>Annals of Oncology</i> , 2008, 19, 473-480.	1.2	36
39	Imatinib mesilate for the treatment of gastrointestinal stromal tumour. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1211-1222.	1.8	19
40	Medullary thyroid cancer treated by capecitabine. <i>Anti-Cancer Drugs</i> , 2007, 18, 831-834.	1.4	8
41	Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. <i>Breast</i> , 2007, 16, 352-358.	2.2	15